Full Article - PDF

Published: 2020-11-20

Page: 63-68


Department of Medical Biochemistry, College of Health Science, Benue State University, Makurdi, Nigeria.


Department of Medical Biochemistry, College of Medicine, University of Nigeria, Enugu Campus, Enugu, Nigeria.


Department of Medical Biochemistry, College of Medicine, University of Nigeria, Enugu Campus, Enugu, Nigeria.


Cross River State Ministry of Health, Cross River, Calabar, Nigeria.


Department of Medical Biochemistry, College of Medicine, University of Nigeria, Enugu Campus, Enugu, Nigeria.

*Author to whom correspondence should be addressed.


Chronic liver disease is one of the major health issues which occur throughout the world irrespective of age, sex, region or race. Liver diseases have being ranked the fifth most common cause of death and the second leading cause of mortality amongst all digestive diseases with approximately 2 million deaths per year worldwide. Aimed at determining the relative prevalence of chronic liver diseases in Nigeria, this shows that up to 46% of global diseases and 59% of the mortality is due to chronic liver diseases and almost 35 million people in the world die of chronic diseases with liver disease rate steadily increasing over the years. In Nigeria, (35 million) 2-20% of the population, are infected with hepatitis B and C virus with a prevalence rate of 4.3%-23.3% and 0.5-15% been reported respectively from different part of the country depending on the geographical location. A prevalence rate of 4.3% was reported from Port Harcourt, 5.7% from Ilorin, 11.6% from Maiduguri, and 8.3% from Zaria, 6.78% from Ado-Ekiti among pregnant women, 13.50% from Lagos, 11.50% from Abuja Urban among HIV Patients with a seroprevalence of 23.3% been reported among patients attending all clinics in Kano.

Keywords: Epidemiology, Chronic liver disease (CLD), Nigeria, Hepatitis B and Hepatitis C Prevalence.

How to Cite

ALI, A. S., IKANI, O. R., ONYEKWELU, K. C., OBI, O. S., & OGBONNA, E. C. (2020). EPIDEMIOLOGY OF CHRONIC LIVER DISEASE IN NIGERIA: A REVIEW. Asian Journal of Advances in Medical Science, 2(1), 63–68. Retrieved from https://mbimph.com/index.php/AJOAIMS/article/view/1716


Download data is not yet available.


Abdel-Misih SRZ, Bloomston M. Liver anatomy. Surgical Clinics of North America. 2010;90(4):643-653.


Vidona WB, Wadioni A. Assessment of liver histomorphology and curative effect of chloroform extract of telfairia occidentalis seed on Carbon Tetrachloride (CCL) induced liver toxicity in wistar rats. J Biomedical Sci. 2018;7(1):4.

DOI: 10.4172/2254-609X.100083.

Kim IH, Kisseleva T, Brenner DA. Aging and liver disease. Curr Opin Gastroenterol. 2015;31:184-191. Supporting Information Additional Supporting Information may be found at onlinelibrary.wiley.com

Saab S, Manne V, Nieto J, Schwimmer JB, Chalasani NP. Nonalcoholic fatty liver disease in Latinos. Clin Gastroenterol Hepatol. 2016;14:5-12.

Noureddin M, Yates KP, Vaughn IA, Neuschwander-Tetri BA, Sanyal AJ, McCullough A. et al. Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology. 2013;58:1644-1654.

Istock@medicine.net retrieved on 5th October, 2020 from Available:https://www.medicinenet.com/liver_disease/article.htm

WHO; 2020.

Available:http://www.who.int/hepatitis B/keyfacts/ 2020. Accessed on October, 2020.

Amarapurkar DN, Hashimoto E, Lesmana LA, Sollano JD, Chen PJ, Goh KL. Asia-pacific working party on NAFLD. How common is non-alcoholic fatty liver disease in the Asia–Pacific region and are there local differences? J Gastroenterol Hepatol. 2007;22:788–793.

Basharo WM, Maier M. Prevalence of chronic liver disease caused by HBV and HCV in Nigeria, compare with European countries. Medical Reproductive Case Studies. 2018;3(2):157.

Stanaway JD, Afshin A, Gakidou E. et al. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1923–94.

Murray CJ, Lopez AD. Evidence-based health policy – lessons from the Burden of Disease Study. Science. 1996;274:740-743.

European association for the study of the liver. EASL clinical practice guidelines: management of alcohol‐related liver disease. J Hepatol. 2018;69:154‐181.

Sarin SK, Rakhi M. Global burden of liver disease: A true burden on health sciences and economics. Retrieved from info@worldgastroenterology.org on October; 2020.

Nimzing G, Simon DT. Management of liver disease in Nigeria. Clin Med. 2007;7:439–41.

Lim YS, Kim WR. The global impact of hepatic fibrosis and end-stage liver disease. Clin Liver Dis. 2008;12:733–746.

Sadaf GS, Saeid S, Catherine B, Kevin SI, Shahin M. et al. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5:245–66.

Younossi ZM. The epidemiology of nonalcoholic steatohepatitis. Clin Liver Dis. 2018;11:92-94.

Garg V, Garg H, Khan A, Trehanpati N, Kumar A, Sharma BC, Sakhuja P, Sarin SK. Granulocyte colony–stimulating factor mobilizes CD34+ cells and improves survival of patients with acute-on-chronic liver failure. Gastroenterology. 2012;142:505–512.

Lapointe-Shaw L, Georgie F, Carlone D. et al. Identifying cirrhosis, decompensated cirrhosis and hepatocellular carcinoma in health administrative data: a validation study. PLoS One. 2018;13:e0201120.

Maisanda BW, Manfred M. Prevalence of chronic liver diseases caused by HBV and HCV in Nigeria in Comparison with European Countries. Med Rep Case Stud. 2018;3:157.


Berinyuy BE, Alawode RA, Mohammed AB, Babalola BS. et al. Prevalence of Hepatitis B Virus in Nigeria: Review update. Annal Pub Health & Epidemiol. 2019;1(1). APHE.MS.ID.000501.

Opaleye OO, Fagbami AH, Lalremruata A, Kun JF. Prevalence and association of human parvovirus B19V with hepatitis B and C viruses in Nigeria. J Med Virol. 2011;83:710-716.

WHO. Hepatitis B; 2020.

Available:https://www.who.int/news-room/factsheet/detail/hepatitis-b. 2020. retrieved on October, 2020.

Saidu AY, Salihu Y, Umar AA, Muhammad BS, Abdullahi I. Seroprevalence of Hepatitis B surface antigen among pregnant women attending ante-natal clinics in Sokoto. Metropolis Journal of Nursing and Health Science. 2015;4:46-50.

Olusegun A, Ijarotimi O, Obasi E, Anthony-Nwojo NG, Ndububa DA. A Southwest Nigerian tertiary hospital 5-year study of the pattern of liver disease admission. Niger J Gastroenterol Hepatol. 2020;12:18-23.

Ndububa DA, Ojo OS, Adetiloye VA, Aladegbaiye AO, Adebayo RA, Adekanle O. The contribution of alcohol to chronic liver disease in patients from South-West Nigeria. Niger J Clin Pract. 2010;13:360-4.

Kooffreh-Ada M, Okpara H, Oku A, Ikekwaba PA. Risk factors of chronic liver disease amongst patients receiving care in a gastroenterogy practice in Calabar. IOSR J Dent Sci. 2015;14:6-13.

Nandi IG, Olu-Eddo AN, Childhood Liver Disease in Nigeria: A 25 (1986-2010) Years Histopathological Study. J. Biomed. Sci Res. 2020:29(1):121.

Adewole OO, Anteyi E, Ajuwon Z, Wada I, Elegba F et al. Hepatitis B and C virus co-infection in Nigerian patients with HIV infection. J Infect Dev Ctries. 2009;3:369- 375.

Ahmed PA, Ulonnam CC, Mohammed-Nafiu R, Ballong J, Nwankwo G. Pattern of liver diseases among children attending the National Hospital Abuja, Nigeria. Niger J Paed. 2016;43:46-50.